Our mission is to improve the lives of lung transplant patients and their families.

Antibody-mediated rejection

Antibody-mediated rejection is another form of rejection. This form of rejection is caused by anti-HLA antibodies that target your transplanted lung(s). These antibodies can be present before transplant (especially if you have had a previous pregnancy, transplant, or blood transfusion) or can develop after transplant.

Treatments for antibody-mediated rejection are different than those used for T-lymphocyte rejection. Treatments can include plasmapheresis, intravenous immunoglobulin (IVIG), Rituxan (rituximab), and Velcade (bortezomib).

related resources

Sign up for updates
Join our community and receive the latest news about lung transplant, including research, inspiring stories, and resources.
Make a donation
Your tax-deductible donation brings us closer to creating a world where all lung transplant patients live long, healthy lives.
The Lung Transplant Foundation is a 501(c)3 non-profit organization.
Provide Website Feedback
Site Design by:
The Design Booth

Disclaimer: This website does not provide medical advice. The information, including but not limited to text, graphics, images, and other material contained on this website are for informational purposes only. No material on this site is intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health care provider with any questions you may have regarding a medical condition or treatment before undertaking any new health care regimen. Never disregard any professional medical advice or delay in seeking care because of something you have read on this website.

Terms of Use